Like finally seeing all the gears of a watch and how
they work together, researchers from UCLA and UC Berkeley have, for the
first time ever, solved the puzzle of how the various components of an
entire telomerase enzyme complex fit together and function in a
three-dimensional structure.
The creation of the first complete visual map of the telomerase
enzyme – which is known to play a significant role in aging and most
cancers – represents a breakthrough that could open up a host of new
approaches to fighting disease, the researchers said.
"Everyone in the field wants to know what telomerase looks like,
and there it was. I was so excited, I could hardly breathe," said Juli
Feigon, a UCLA professor of chemistry and biochemistry and a senior
author of the study. "We were the first to see it."
The scientists report the positions of each component of the
enzyme relative to one another and the complete organisation of the
enzyme's active site. In addition, they demonstrate how the different
components contribute to the enzyme's activity, uniquely correlating
structure with biochemical function. Their research is published in
Nature.
"We combined every single possible method we could get our
hands on to solve this structure and used cutting-edge technological
advances," said co-first author Jiansen Jiang, a researcher who works
with Feigon. "This breakthrough would not have been possible five years
ago."
"We really had to figure out how everything fit together, like a
puzzle," said co-first author Edward Miracco, a National Institutes of
Health postdoctoral fellow in Feigon's laboratory. "When we started
fitting in the high-resolution structures to the blob that emerged from
electron microscopy, we realized that everything was fitting in and made
sense with decades of past biochemistry research. The project just
blossomed, and the blob became a masterpiece."
The telomerase enzyme is a mixture of components that unite
inside our cells to maintain the protective regions at the ends of our
chromosomes, which are called telomeres. Telomeres act like the plastic
tips at the end of shoelaces, safeguarding important genetic
information. But each time a cell divides, these telomeres shorten, like
the slow-burning fuse of a time bomb. Eventually, the telomeres erode
to a point that is no longer tolerable for cells, triggering the cell
death that is a normal part of the aging process.
While most cells have relatively low levels of telomerase, 80
percent to 90 percent of cancer cells have abnormally high telomerase
activity. This prevents telomeres from shortening and extends the life
of these tumorigenic cells — a significant contributor to cancer
progression.
The new discovery creates tremendous potential for
pharmaceutical development that takes into account the way a drug and
target molecule might interact, given the shape and chemistry of each
component. Until now, designing a cancer-fighting drug that targeted
telomerase was much like shooting an arrow to hit a bulls-eye while
wearing a blindfold. With this complete visual map, the researchers are
starting to remove that blindfold.
"Inhibiting telomerase won't hurt most healthy cells but is
predicted to slow down the progression of a broad range of cancers,"
said Miracco. "Our structure can be used to guide targeted drug
development to inhibit telomerase, and the model system we used may also
be useful to screen candidate drugs for cancer therapy."
The researchers solved the structure of telomerase in
Tetrahymena thermophila,
the single-celled eukaryotic organism in which scientists first
identified telomerase and telomeres, leading to the 2009 Nobel Prize in
medicine or physiology. Research on Tetrahymena telomerase in the lab of
co-senior author Kathleen Collins, a professor of molecular and cell
biology at UC Berkeley, laid the genetic and biochemical groundwork for
the structure to be solved.
An illustration of how telomerase elongates telomere ends progressively. Credit: Uzbas, F
"The success of this project was absolutely dependent on the collaboration among our research groups," said Feigon.
"At every step of this project, there were difficulties," she added.
"We had so many technical hurdles to overcome, both in the electron
microscopy and the biochemistry. Pretty much every problem we could
have, we had – and yet at each stage these hurdles were overcome in an
innovative way."
One of the biggest surprises, the researchers said, was the role of the protein p50, which acts as a hinge in
Tetrahymena
telomerase to allow dynamic movement within the complex; p50 was found
to be an essential player in the enzyme's activity and in the
recruitment of other proteins to join the complex.
"The beauty of this structure is that it opens up a whole new world of
questions for us to answer," Feigon said. "The exact mechanism of how
this complex interacts with the telomere is an active area of future
research."